The RSVpreF vaccine contains two preF proteins chosen to enhance protection against respiratory syncytial virus A and B. Credit: NIAID / commons.wikimedia.org.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Pfizer’s investigational vaccine candidate, PF-06928316 or RSVpreF, to prevent respiratory syncytial virus (RSV) in the elderly.

The RSV vaccine is intended to prevent RSV-caused lower respiratory tract disease in people aged 60 years or above.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

RSVpreF contains two prefusion F (preF) proteins chosen to enhance protection against RSV A and B.

The regulatory agency based its decision largely on the positive data from a proof-of-concept Phase IIa trial of RSVpreF in a human viral challenge model, in healthy adults aged 18 to 50 years.

In the trial, the safety, immunogenicity, and efficacy of a 120µg single dose of the vaccine were assessed.

See Also:

In September last year, the company commenced the international, randomised, double-blind, placebo-controlled Phase III RENOIR trial in adults aged 60 years or above. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This trial, which is studying the safety, efficacy, and immunogenicity of one dose of the vaccine, is currently underway.

RSVpreF’s safety and efficacy in preventing moderate to severe lower respiratory tract illness in the first RSV season will be the primary goal of the trial.

Pfizer Vaccine Research and Development senior vice-president and head Kathrin Jansen said: “The decision is a significant step forward in our efforts to help protect vulnerable populations, particularly older adults, against certain potentially serious respiratory illnesses, including RSV. 

“The clinical and economic burden of RSV represents a critical need, and we look forward to our ongoing dialogue with the FDA to accelerate the development of our RSV vaccine candidate.”